1. Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
- Author
-
Xuxiang Zhang, Heng Wu, Beisha Tang, and Jifeng Guo
- Subjects
Gaucher’s disease ,Parkinson’s disease ,Glucocerebrosidase ,Mechanisms ,Biomarker ,Therapy ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Parkinson’s disease (PD) is the second most common neurodegenerative disease. The development of PD is closely linked to genetic and environmental factors, with GBA1 variants being the most common genetic risk. Mutations in the GBA1 gene lead to reduced activity of the coded enzyme, glucocerebrosidase, which mediates the development of PD by affecting lipid metabolism (especially sphingolipids), lysosomal autophagy, endoplasmic reticulum, as well as mitochondrial and other cellular functions. Clinically, PD with GBA1 mutations (GBA1-PD) is characterized by particular features regarding the progression of symptom severity. On the therapeutic side, the discovery of the relationship between GBA1 variants and PD offers an opportunity for targeted therapeutic interventions. In this review, we explore the genotypic and phenotypic correlations, etiologic mechanisms, biomarkers, and therapeutic approaches of GBA1-PD and summarize the current state of research and its challenges.
- Published
- 2024
- Full Text
- View/download PDF